150 related articles for article (PubMed ID: 35655437)
1. Mutation of KRAS in colorectal adenocarcinoma in Greenland.
Mousavi N; Truelsen SLB; Bernth-Andersen S; Koch A; Heegaard S
APMIS; 2022 Aug; 130(8):493-497. PubMed ID: 35655437
[TBL] [Abstract][Full Text] [Related]
2. [The frequency and spectrum of KRAS mutations in metastatic colorectal cancer].
Mazurenko NN; Gagarin IM; Tsyganova IV; Mochal'nikova VV; Breder VV
Vopr Onkol; 2013; 59(6):751-5. PubMed ID: 24624786
[TBL] [Abstract][Full Text] [Related]
3. Computational analysis of KRAS mutations: implications for different effects on the KRAS p.G12D and p.G13D mutations.
Chen CC; Er TK; Liu YY; Hwang JK; Barrio MJ; Rodrigo M; Garcia-Toro E; Herreros-Villanueva M
PLoS One; 2013; 8(2):e55793. PubMed ID: 23437064
[TBL] [Abstract][Full Text] [Related]
4. [Detection of KRAS gene mutation and its clinical significance in colorectal adenocarcinoma].
Xu C; Liu YL; Huang J; He DM; Hou YY; Ji Y; Hou J; Lu SH; Xu JF; Hu Q; Shi Y; Zhao LJ; Tan YS
Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):667-70. PubMed ID: 23302307
[TBL] [Abstract][Full Text] [Related]
5. Characterization of rare transforming KRAS mutations in sporadic colorectal cancer.
Tong JH; Lung RW; Sin FM; Law PP; Kang W; Chan AW; Ma BB; Mak TW; Ng SS; To KF
Cancer Biol Ther; 2014 Jun; 15(6):768-76. PubMed ID: 24642870
[TBL] [Abstract][Full Text] [Related]
6. IMPACT OF KRAS MUTATIONS IN CLINICAL FEATURES IN COLORECTAL CANCER.
Zanatto RM; Santos G; Oliveira JC; Pracucho EM; Nunes AJF; Lopes-Filho GJ; Saad SS
Arq Bras Cir Dig; 2020; 33(3):e1524. PubMed ID: 33331426
[TBL] [Abstract][Full Text] [Related]
7. [Correlation between KRAS mutations and clinicopathologic features in colorectal carcinomas].
Gao J; Zhang J; Lu T; Li XY; Jia N; Liang ZY
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):595-8. PubMed ID: 23157826
[TBL] [Abstract][Full Text] [Related]
8. Tumor heterogeneity revealed by KRAS, BRAF, and PIK3CA pyrosequencing: KRAS and PIK3CA intratumor mutation profile differences and their therapeutic implications.
Kosmidou V; Oikonomou E; Vlassi M; Avlonitis S; Katseli A; Tsipras I; Mourtzoukou D; Kontogeorgos G; Zografos G; Pintzas A
Hum Mutat; 2014 Mar; 35(3):329-40. PubMed ID: 24352906
[TBL] [Abstract][Full Text] [Related]
9. Correlation between
Aktar S; Islam F; Cheng T; Gamage SMK; Choudhury IN; Islam MS; Lu CT; Hamid FB; Ishida H; Abe I; Xie N; Gopalan V; Lam AK
Genes (Basel); 2023 Sep; 14(9):. PubMed ID: 37761948
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.
Abubaker J; Bavi P; Al-Haqawi W; Sultana M; Al-Harbi S; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Uddin S; Al-Kuraya KS
J Pathol; 2009 Dec; 219(4):435-45. PubMed ID: 19824059
[TBL] [Abstract][Full Text] [Related]
11. [KRAS gene somatic mutations in Chilean patients with colorectal cancer].
Hurtado C; Encina G; Wielandt AM; Zárate AJ; Castro M; Carrillo K; Kronberg U; López-Köstner F
Rev Med Chil; 2014 Nov; 142(11):1407-14. PubMed ID: 25694286
[TBL] [Abstract][Full Text] [Related]
12. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
13. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
Neumann J; Zeindl-Eberhart E; Kirchner T; Jung A
Pathol Res Pract; 2009; 205(12):858-62. PubMed ID: 19679400
[TBL] [Abstract][Full Text] [Related]
14. KRAS and BRAF mutations in Serbian patients with colorectal cancer.
Jakovljevic K; Malisic E; Cavic M; Krivokuca A; Dobricic J; Jankovic R
J BUON; 2012; 17(3):575-80. PubMed ID: 23033302
[TBL] [Abstract][Full Text] [Related]
15. Wobble-enhanced ARMS method for detection of KRAS and BRAF mutations.
Hamfjord J; Stangeland AM; Skrede ML; Tveit KM; Ikdahl T; Kure EH
Diagn Mol Pathol; 2011 Sep; 20(3):158-65. PubMed ID: 21817902
[TBL] [Abstract][Full Text] [Related]
16. Impact of genetic profiles on the efficacy of anti-EGFR antibodies in metastatic colorectal cancer with KRAS mutation.
Kishiki T; Ohnishi H; Masaki T; Ohtsuka K; Ohkura Y; Furuse J; Sugiyama M; Watanabe T
Oncol Rep; 2014 Jul; 32(1):57-64. PubMed ID: 24839940
[TBL] [Abstract][Full Text] [Related]
17. KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies.
Maus MK; Grimminger PP; Mack PC; Astrow SH; Stephens C; Zeger G; Hsiang J; Brabender J; Friedrich M; Alakus H; Hölscher AH; Lara P; Danenberg KD; Lenz HJ; Gandara DR
Lung Cancer; 2014 Feb; 83(2):163-7. PubMed ID: 24331409
[TBL] [Abstract][Full Text] [Related]
18. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.
De Roock W; Jonker DJ; Di Nicolantonio F; Sartore-Bianchi A; Tu D; Siena S; Lamba S; Arena S; Frattini M; Piessevaux H; Van Cutsem E; O'Callaghan CJ; Khambata-Ford S; Zalcberg JR; Simes J; Karapetis CS; Bardelli A; Tejpar S
JAMA; 2010 Oct; 304(16):1812-20. PubMed ID: 20978259
[TBL] [Abstract][Full Text] [Related]
19. The prevalence and prognostic significance of KRAS mutation in bladder cancer, chronic myeloid leukemia and colorectal cancer.
Ouerhani S; Bougatef K; Soltani I; Elgaaied AB; Abbes S; Menif S
Mol Biol Rep; 2013 Jun; 40(6):4109-14. PubMed ID: 23640097
[TBL] [Abstract][Full Text] [Related]
20. Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: determination of frequency, distribution pattern in Indian colorectal carcinoma.
Bisht S; Ahmad F; Sawaimoon S; Bhatia S; Das BR
Med Oncol; 2014 Sep; 31(9):124. PubMed ID: 25073438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
